Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53


Levels of the tumour suppressor protein p53 are increased in response to a variety of DNA damaging agents. DNA damage-induced phosphorylation of p53 occurs at serine-15 in vivo. Phosphorylation of p53 at serine-15 leads to a stabilization of the polypeptide by inhibiting its interaction with Mdm2, a protein that targets p53 for ubiquitin-dependent degradation. However, the mechanisms by which DNA damage is signalled to p53 remain unclear. Here, we report the identification of a novel DNA-activated protein kinase that phosphorylates p53 on serine-15. Fractionation of HeLa nuclear extracts and biochemical analyses indicate that this kinase is distinct from the DNA-dependent protein kinase (DNA-PK) and corresponds to the human cell cycle checkpoint protein ATR. Immunoprecipitation studies of recombinant ATR reveal that catalytic activity of this polypeptide is required for DNA-stimulated phosphorylation of p53 on serine-15. These data suggest that ATR may function upstream of p53 in a signal transduction cascade initiated upon DNA damage and provide a biochemical assay system for ATR activity.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 3
Figure 2
Figure 4


  • Artuso M, Esteve A, Bresil H, Vuillaume M and Hall J. . 1995 Oncogene 11: 1427–1435.

  • Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y. . 1998 Science 281: 1674–1677.

  • Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakaguchi KA, Apella E, Kastan MB and Siliciano JD. . 1998 Science 281: 1677–1679.

  • Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL and Friend SH. . 1998 EMBO J. 17: 159–169.

  • Dvir A, Stein LY, Calore BL and Dynan WS. . 1993 J. Biol. Chem. 268: 10440–10447.

  • Elledge SJ. . 1996 Science 274: 1664–1672.

  • Gately DP, Hittle JC, Chan GK and Yen TJ. . 1998 Mol. Biol. Cell. 9: 2361–2374.

  • Giaccia AJ and Kastan MB. . 1998 Genes Dev. 12: 2973–2983.

  • Gottlieb TM and Jackson SP. . 1993 Cell 72: 131–142.

  • Gottlieb TM and Oren M. . 1997 Biochim. Biophys. Acta 1287: 77–102.

  • Hartley KO, Gell D, Smith GCM, Zhang H, Divecha N, Connelly MA, Admon A, Lees-Miller SP, Anderson CW and Jackson SP. . 1995 Cell 82: 849–856.

  • Hoekstra MF. . 1997 Curr. Opin. Genet. Dev. 7: 170–175.

  • Hupp TR, Meek DM, Midgley CA and Lane DP. . 1992 Cell 71: 875–886.

  • Jackson SP. . 1996 Cancer Surv. 28: 261–279.

  • Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJJ. . 1992 Cell 71: 587–597.

  • Khanna K and Lavin MF. . 1993 Oncogene 8: 3307–3312.

  • Ko LJ and Prives C. . 1996 Genes Dev. 10: 1054–1072.

  • Lakin ND, Weber P, Stankovic T, Rottinghaus ST, Taylor AM and Jackson SP. . 1996 Oncogene 13: 2707–2716.

  • Levine AJ. . 1997 Cell 88: 323–331.

  • Longhese MP, Foiani M, Muzi-Falconi M, Lucchini G and Plevani P. . 1998 EMBO J. 17: 5525–5528.

  • Paulovich AG, Toczyski DP and Hartwell LH. . 1997 Cell 88: 315–321.

  • Powis G, Bonjouklain R, Berggren MM, Gallegos A, Abraham R, Ashdel C, Zazkow L, Matter WF, Dodge J, Grindley G and Vlamos CJ. . 1994 Cancer Res. 95: 2419–2423.

  • Prives C. . 1998 Cell 95: 5–8.

  • Rotman G and Shiloh Y. . 1997 Cancer Surv. 29: 285–304.

  • Shieh S-Y, Ikeda M, Taya Y and Prives C. . 1997 Cell 91: 325–334.

  • Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB. . 1997 Genes Dev. 11: 3471–3481.

  • Smith GCM and Jackson SP. . 1999 Genes Dev. (in press).

  • Song Q, Lees-Miller SP, Kumar S, Zhang N, Chan DW, Smith GCM, Jackson SP, Alnemri ES, Litwack G and Lavin MF. . 1996 EMBO J. 15: 3238–3246.

  • Steegenga WT, van der Eb AJ and Jochemsen AG. . 1996 J. Mol. Biol. 263: 103–113.

  • Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cilby WA, Shieh SY, Taya Y, Prives C and Abraham RT. . 1999 Genes Dev. 13: 152–157.

  • Ui M, Okado T, Hazeki K and Hazeki O. . 1995 Trends Biochem. Sci. 20: 303–307.

  • Weinert I. . 1998 Curr. Opin. Genet. Dev. 8: 185–193.

  • Woo RA, McLure KG, Lees-Miller SP, Rancourt DE and Lee PWK. . 1998 Nature 394: 700–704.

  • Wright WA, Keegan KS, Herendeen DR, Bentley NJ, Carr AM, Hoekstra MF and Concannon P. . 1998 Proc. Natl. Acad. Sci. USA 95: 7445–7450.

Download references


We thank members of the SPJ laboratory for their advice and support. In particular, we thank Graeme Smith, John Rouse, Daniel Durocher and Susan Critchlow for helpful discussions. We also thank David Lane for advice and support. Cell lines expressing ATR derivatives were a generous gift from Stephen Friend, and cyclin A/cdk2 was a gift from Mark Jackman and Jon Pines. This work was funded by grants from the Cancer Research Campaign, the Kay Kendall Leukaemia Fund and the A-T Children's Project.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lakin, N., Hann, B. & Jackson, S. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 18, 3989–3995 (1999).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • p53
  • ATR
  • ATM
  • DNA-PK
  • ataxia telangiectasia
  • DNA damage

Further reading


Quick links